Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$34.51 USD
-0.09 (-0.26%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $34.46 -0.05 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Tarsus Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 227 | 217 | 172 | 168 | 58 |
Receivables | 18 | 4 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 5 | 4 | 2 | 0 |
Total Current Assets | 256 | 225 | 176 | 171 | 58 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 0 |
Investments & Advances | 1 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 4 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 1 | 1 | 0 | 0 |
Total Assets | 265 | 228 | 179 | 172 | 58 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 24 | 10 | 9 | 4 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 6 | 3 | 1 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 37 | 15 | 11 | 5 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 30 | 19 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 0 | 1 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 69 | 35 | 12 | 6 | 1 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 63 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 442 | 302 | 213 | 199 | 0 |
Retained Earnings | -245 | -109 | -47 | -33 | -6 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 197 | 193 | 167 | 166 | 57 |
Total Liabilities & Shareholder's Equity | 265 | 228 | 179 | 172 | 58 |
Total Common Equity | 197 | 193 | 167 | 166 | -6 |
Shares Outstanding | 33.10 | 26.60 | 20.60 | 20.30 | NA |
Book Value Per Share | 5.95 | 7.25 | 8.09 | 8.18 | 0.00 |
Fiscal Year End for Tarsus Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 324 | 299 | 227 | 247 | 178 |
Receivables | 31 | 31 | 18 | 6 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 2 | 4 | 3 | 0 | 0 |
Other Current Assets | 6 | 7 | 8 | 6 | 5 |
Total Current Assets | 363 | 341 | 256 | 259 | 183 |
Net Property & Equipment | 2 | 1 | 1 | 2 | 2 |
Investments & Advances | 3 | 0 | 1 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 4 | 4 | 4 | 4 | 0 |
Deposits & Other Assets | 3 | 1 | 2 | 1 | 1 |
Total Assets | 377 | 349 | 265 | 268 | 189 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 44 | 37 | 24 | 15 | 9 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 8 | 6 | 13 | 8 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 52 | 43 | 37 | 23 | 15 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 72 | 30 | 30 | 30 | 25 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 2 | 2 | 2 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 125 | 74 | 69 | 55 | 41 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 566 | 556 | 442 | 416 | 311 |
Retained Earnings | -314 | -280 | -245 | -203 | -164 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 252 | 275 | 197 | 214 | 148 |
Total Liabilities & Shareholder's Equity | 377 | 349 | 265 | 268 | 189 |
Total Common Equity | 252 | 275 | 197 | 214 | 148 |
Shares Outstanding | 37.70 | 37.70 | 33.10 | 33.10 | 26.80 |
Book Value Per Share | 6.69 | 7.30 | 5.95 | 6.45 | 5.51 |